Cardiol Therapeutics Inc.
CRDL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001702123
No open-market purchases or sales by Cardiol Therapeutics Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $31.3M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Cardiol Therapeutics Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 43 | 38 | −5 |
| Shares | 7.49M | 7.72M | +226.3K (+3.0%) |
| Value | $9.60M | $7.44M | −$2.16M (−22.6%) |
New holders (4)
Institutions that held Cardiol Therapeutics Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Asset Management Americas Inc | 55,000 | $53.4K | 0.00% |
| Independent Advisor Alliance | 10,000 | $9.70K | 0.00% |
| Tower Research Capital LLC (TRC) | 118 | $114 | 0.00% |
| Stone House Investment Management, LLC | 50 | $48 | 0.00% |
Sold out (9)
Institutions that held Cardiol Therapeutics Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citadel Advisors LLC | 38,110 | $48.8K |
| LPL Financial LLC | 18,310 | $23.4K |
| Susquehanna International Group, LLP | 17,364 | $22.2K |
| Wealth Enhancement Advisory Services, LLC | 13,538 | $17.3K |
| Marshall Wace, LLP | 13,193 | $16.9K |
| New Wave Wealth Advisors LLC | 1,000 | $1.28K |
| Wingate Wealth Advisors, Inc. | 85 | $109 |
| MAI Capital Management | 25 | $32 |
| Toronto Dominion Bank | 1 | $1 |